在T2N1激素受体阳性、ERBB2阴性的乳腺癌患者中，最大标准化摄取值高可能与T2b（≥4厘米）的关联比与T2a（<4厘米）的关联更大。 - Suppr | 超能文献

High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer.

作者信息

Altundag Kadri

机构信息

MKA Breast Cancer Clinic, Tepe Prime, 06800, Ankara, Turkey.

出版信息

Breast Cancer Res Treat. 2023 Apr;198(2):403. doi: 10.1007/s10549-023-06869-4. Epub 2023 Feb 3.

DOI:10.1007/s10549-023-06869-4

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer.在T2N1激素受体阳性、ERBB2阴性的乳腺癌患者中，最大标准化摄取值高可能与T2b（≥4厘米）的关联比与T2a（<4厘米）的关联更大。

Breast Cancer Res Treat. 2023 Apr;198(2):403. doi: 10.1007/s10549-023-06869-4. Epub 2023 Feb 3.

2

Prognostic significance of pretreatment F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy.治疗前F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对接受辅助化疗的T2N1激素受体阳性、ERBB2阴性乳腺癌患者的预后意义。

Breast Cancer Res Treat. 2023 Apr;198(2):207-215. doi: 10.1007/s10549-022-06852-5. Epub 2023 Jan 12.

3

Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancer-special reference to tumor size.从临床病理角度验证新提出的 T 分期（肿瘤、淋巴结、转移分类第七版）在非小细胞肺癌中的应用——特别关注肿瘤大小。

J Thorac Oncol. 2010 Jan;5(1):45-8. doi: 10.1097/JTO.0b013e3181c0996c.

4

Appropriate surgical modalities for stages T2a and T2b in the eighth TNM classification of lung cancer.第八版肺癌 TNM 分期中 T2a 和 T2b 期的合适手术方式。

Sci Rep. 2017 Oct 12;7(1):13050. doi: 10.1038/s41598-017-13495-w.

5

Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a large-scale nationwide database.第 7 版肺癌 TNM 分期中对非小细胞肺癌内脏胸膜侵犯的分类：基于大规模全国性数据库的验证分析。

J Thorac Oncol. 2013 May;8(5):606-11. doi: 10.1097/JTO.0b013e31828632b8.

6

Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer.质子治疗和碳离子治疗大型（T2a-T2bN0M0）非小细胞肺癌的长期结果。

J Thorac Oncol. 2013 Jun;8(6):726-35. doi: 10.1097/JTO.0b013e318288ab02.

7

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.Her4受体亚型表达在三阴性和Her2阳性乳腺癌患者中的预后价值。

BMC Cancer. 2013 Sep 24;13:437. doi: 10.1186/1471-2407-13-437.

8

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.一项关于肿瘤大小和 KRAS 突变对淋巴结阴性非小细胞肺癌辅助铂类化疗生存获益影响的汇总探索性分析。

J Thorac Oncol. 2012 Jun;7(6):963-72. doi: 10.1097/JTO.0b013e31824fe9e6.

9

Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.对于最大标准化摄取值小于5.3的非小细胞肺癌纵隔淋巴结患者，可能无需进行纵隔镜检查。

J Thorac Cardiovasc Surg. 2008 Mar;135(3):615-9. doi: 10.1016/j.jtcvs.2007.09.029. Epub 2008 Jan 11.

10

The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.新生物标志物更新在新辅助化疗治疗乳腺癌分期中的应用：治疗后预后生物因素在分期中的纳入。

JAMA Oncol. 2016 Jul 1;2(7):929-36. doi: 10.1001/jamaoncol.2015.6478.

本文引用的文献

1

Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.新辅助化疗后高危早期乳腺癌骨髓中播散肿瘤细胞的结果和临床病理特征：I-SPY SURMOUNT 研究。

Breast Cancer Res Treat. 2023 Apr;198(2):383-390. doi: 10.1007/s10549-022-06803-0. Epub 2023 Jan 23.